Wound care includes negative-pressure wound therapy (NPWT, e.g., 3M/KCI V.A.C.), advanced dressings, cellular and tissue products (CTPs/skin substitutes), and emerging electrical stimulation and oxygen therapies. Products include advanced dressings, negative pressure wound therapy and skin substitutes. Coverage of skin substitutes has drawn CMS attention, with local coverage policies tightening evidence requirements. Outcomes such as healing rate and time to closure drive adoption.

Why it matters

Diabetic foot ulcers and venous leg ulcers drive demand. CMS LCDs on skin substitutes have repeatedly reshaped commercial dynamics.

Common pitfalls

•A common pitfall is misclassifying a novel wound care product, leading to incorrect regulatory submissions and delays. Another mistake is failing to adequately validate sterilization processes for sterile wound care devices. Manufacturers often underestimate the clinical data required for advanced wound care therapies, especially those involving biological components.
•Overlooking specific labeling requirements for combination products, such as drug-device wound dressings, can lead to non-compliance.
•Ignoring post-market surveillance data for long-term wound healing outcomes can result in missed opportunities for product improvements or safety signals.

Sources

WoundSource · WoundSource
MedTech Dive · MedTech Dive
AdvaMed - Industry Reports · AdvaMed
Non-powered Suction Apparatus for Negative Pressure Wound Therapy · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.